EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Withaferin A as a Potential Therapeutic Target for the Treatment of Angiotensin II-Induced Cardiac Cachexia

Vasa Vemuri iD, Nicholas Kratholm, Darini Nagarajan, Dakotah Cathey, Ahmed Abdelbaset-Ismail, Yi Tan, Alex Straughn, Lu Cai iD, Jiapeng Huang iD, Sham S Kakar

Cells · 2024

DOI: 10.3390/cells13090783 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Vasa Vemuri und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, University of Louisville, Louisville, KY 40202, USA. Hauptthemen laut MEDLINE: Angiotensin II, Cachexia, Myocardium, Withanolides. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIEHS NIH HHS, NIAID NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In our previous studies, we showed that the generation of ovarian tumors in NSG mice (immune-compromised) resulted in the induction of muscle and cardiac cachexia, and treatment with withaferin A (WFA; a steroidal lactone) attenuated both muscle and cardiac cachexia. However, our studies could not address if these restorations by WFA were mediated by its anti-tumorigenic properties that might, in turn, reduce the tumor burden or WFA’s direct, inherent anti-cachectic properties. To address this important issue, in our present study, we used a cachectic model induced by the continuous infusion of Ang II by implanting osmotic pumps in immunocompetent C57BL/6 mice. The continuous infusion of Ang II resulted in the loss of the normal functions of the left ventricle (LV) (both systolic and diastolic), including a significant reduction in fractional shortening, an increase in heart weight and LV wall thickness, and the development of cardiac hypertrophy. The infusion of Ang II also resulted in the development of cardiac fibrosis, and significant increases in the expression levels of genes (ANP, BNP, and MHCβ) associated with cardiac hypertrophy and the chemical staining of the collagen abundance as an indication of fibrosis. In addition, Ang II caused a significant increase in expression levels of inflammatory cytokines (IL-6, IL-17, MIP-2, and IFNγ), NLRP3 inflammasomes, AT1 receptor, and a decrease in AT2 receptor. Treatment with WFA rescued the LV functions and heart hypertrophy and fibrosis. Our results demonstrated, for the first time, that, while WFA has anti-tumorigenic properties, it also ameliorates the cardiac dysfunction induced by Ang II, suggesting that it could be an anticachectic agent that induces direct effects on cardiac muscles.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiotensin IICachexiaMyocardiumWithanolidesAnimalsMiceCardiomegalyCytokinesFibrosisMice, Inbred C57BL

Stichwörter der Autor:innen

Ang II-induced cachexiaangiotensin IIcardiac cachexiacardiac disorderscardiac dysfunctioninflammatory cytokineswithaferin A

Substanzen

Angiotensin IICytokineswithaferin AWithanolides

Autor:innen und Institutionen

  • Department of Physiology, University of Louisville, Louisville, KY 40202, USA.
  • Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY 40202, USA.
  • Pediatric Research Institute, Department of Pediatrics, University of Louisville, Louisville, KY 40202, USA.
  • Department of Anesthesiology and Perioperative Medicine, University of Louisville, Louisville, KY 40202, USA.
  • Brown Cancer Center, University of Louisville, Louisville, KY 40202, USA.

ORCID-Profile: Vasa Vemuri, Lu Cai, Jiapeng Huang

Förderung

  • NIEHS NIH HHS
  • NIAID NIH HHS
  • NIGMS NIH HHS
  • NHLBI NIH HHS
  • NCATS NIH HHS
  • NIH HHS
  • National Institute of Health
  • National Institute of Environmental Health Sciences

Zitieren

APA

Vemuri, V., Kratholm, N., Nagarajan, D., Cathey, D., Abdelbaset-Ismail, A., Tan, Y., Straughn, A., Cai, L., Huang, J., & Kakar, S. S. (2024). Withaferin A as a Potential Therapeutic Target for the Treatment of Angiotensin II-Induced Cardiac Cachexia. Cells. https://doi.org/10.3390/cells13090783

Vancouver

Vemuri V, Kratholm N, Nagarajan D, Cathey D, Abdelbaset-Ismail A, Tan Y, et al. Withaferin A as a Potential Therapeutic Target for the Treatment of Angiotensin II-Induced Cardiac Cachexia. Cells. 2024. doi:10.3390/cells13090783

BibTeX
@article{Vemuri2024,
  author = {Vemuri, Vasa and Kratholm, Nicholas and Nagarajan, Darini and Cathey, Dakotah and Abdelbaset-Ismail, Ahmed and Tan, Yi and Straughn, Alex and Cai, Lu and Huang, Jiapeng and Kakar, Sham S},
  title = {Withaferin A as a Potential Therapeutic Target for the Treatment of Angiotensin II-Induced Cardiac Cachexia},
  journal = {Cells},
  year = {2024},
  doi = {10.3390/cells13090783}
}
Kostenlos starten →